Interestingly, dupilumab treatment was found to decrease biomarker concentrations in nasal secretions and nasal polyp tissue including those of eotaxin-2, eotaxin-3, IgE, and IL-13 (40). This evidence concerns the gene IL13 and Nasal polyposis.